More recently, NICE Technology Appraisal TA875 has supported the use of semaglutide 2.4 mg (Wegovy) within specific criteria, including a BMI of 35 kg/m or above (or lower in certain high-risk groups) with at least one weight-related comorbidity
Similarly, a recent study reported that macrophages exposed to a mechanochemically distressed PP mesh significantly upregulate the expression of IL-10, a profibrotic marker (Farr et al
Others respond better to different GLP-1 compounds or combination therapies
Nutrition Journal , 19 (1), 82
As FDA states in their guidance document on the Q-Submission program, Early interaction with FDA on planned non-clinical and clinical studies and careful consideration of FDAs feedback may improve the quality of subsequent submissions, shorten total review times, and facilitate the development process for new devices. While this is not meant to be a general pre-review of your submission, it is there to help you get answers to questions directly from FDAwhich will contribute to a smooth submission and, hopefully, approval
)
